LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE1.7100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6300/ 2
- Ask / Lots1.7500/ 1
- Open / Previous Close--- / 1.7100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 10:26 ET | 300 | 1.71 |
| 10:48 ET | 100 | 1.7094 |
| 10:50 ET | 491 | 1.72 |
| 10:53 ET | 2450 | 1.74 |
| 11:04 ET | 100 | 1.75 |
| 11:38 ET | 200 | 1.735 |
| 12:02 ET | 100 | 1.72 |
| 12:09 ET | 700 | 1.74 |
| 12:14 ET | 538 | 1.71 |
| 12:34 ET | 100 | 1.7 |
| 12:56 ET | 539 | 1.7 |
| 12:57 ET | 100 | 1.69 |
| 01:03 ET | 500 | 1.68 |
| 02:20 ET | 3442 | 1.66 |
| 03:00 ET | 100 | 1.68 |
| 03:12 ET | 180 | 1.665 |
| 03:25 ET | 100 | 1.6673 |
| 03:34 ET | 600 | 1.67 |
| 03:50 ET | 300 | 1.67 |
| 03:57 ET | 891 | 1.7 |
| 03:59 ET | 2178 | 1.71 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 45.0M | -1.9x | --- |
Atara Biotherapeutics Inc | 43.5M | -0.2x | --- |
Kezar Life Sciences Inc | 58.2M | -0.6x | --- |
BioLine RX Ltd | 48.7M | -0.6x | --- |
DURECT Corp | 38.5M | -2.3x | --- |
Kronos Bio Inc | 59.9M | -0.6x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $45.0M |
|---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-0.90 |
Book Value | $1.95 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -371.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
